PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
13.58
0.75–0.9x AVXL's 16.89. Bill Ackman might push for more working capital or better cash management.
13.58
0.75–0.9x AVXL's 16.89. Bill Ackman would recommend finding ways to boost near-cash assets or reduce short-term liabilities.
13.39
0.75–0.9x AVXL's 16.15. Bill Ackman might want more safety or minimal liabilities.
-30.15
Negative interest coverage while AVXL shows 0.00. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
-14.65
Negative short-term coverage while AVXL shows 0.00. Joel Greenblatt would look for cash flow improvements and refinancing catalysts.